MT Newswires
Cytokinetics Insider Sold Shares Worth $1,322,800, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
Cytokinetics Incorporated News
Latest updates and market news for CYTK
10 news
Dec 19 - Dec 25, 2025
Page 1
Zacks
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
RBC Raises Price Target on Cytokinetics to $95 From $87, Keeps Outperform, Speculative Risk
📈
AI Sentiment
Highly Positive
8/10
BioPharma Dive
Cytokinetics set to battle Bristol Myers as FDA approves heart drug
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)?
📈
AI Sentiment
Highly Positive
8/10
Investor's Business Daily
Cytokinetics Wins FDA Approval For Its First Drug, Taking On Bristol Myers
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Cytokinetics Reports Myqorzo Approval for Symptomatic Obstructive Hypertrophic Cardiomyopathy
📈
AI Sentiment
Highly Positive
9/10
GlobeNewswire
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
📊
AI Sentiment
Positive
6/10
Share this news page